(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Vote In favor of Your Favored Kind Of Cheddar- Instructions to Pick the Ideal SUV Size for Seniors
- Audits of Espresso Types: Which Mix Is for You?
- Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces
- Creative Do-It-Yourself Ventures for Each Expertise Level
- 'The Real Housewives of Rhode Island' 1st teaser trailer unveiled: Which Bachelor Nation star is part of the cast? And when does it premiere?
- The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
- Easy to understand Tech: Cell phones for Old in 2024
